Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (30)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nanni, P.
Right arrow Articles by Lollini, P.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nanni, P.
Right arrow Articles by Lollini, P.-L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:261-266, 1999
© 1999 European Society for Medical Oncology

review-article

Cytokine gene therapy: Hopes and pitfalls

P. Nanni1, G. Forni2 and P.-L. Lollini1

1Institute of Cancer Research, University of Bologna Bologna
2Department of Clinical and Biological Sciences, University of Turin Orbassano, Italy

Istituto di Cancerologia, Viale Filopanti 22, 1-40126 Bologna, Italy E-mail. pierluigi{at}lollini.dsnet.it

Transduction of a cytokine gene into neoplastic cells elicits a strong inflammatory host reaction that impairs tumor growth, and a long-lasting immune memory is established following their rejection. These findings have aroused great enthusiasm and expectations. Despite their enhanced immunogenicity, however, the immune reaction provoked by repeated injections of these engineered cells can do little more than inhibit the growth of initial tumors and metastases and is only minimally effective against established forms. Better therapeutic activity is thus being sought by combining such cells with tumor cells engineered with other genes.

cytokines, gene therapy, immune response


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
G. Driessens, M. Hamdane, V. Cool, T. Velu, and C. Bruyns
Highly Successful Therapeutic Vaccinations Combining Dendritic Cells and Tumor Cells Secreting Granulocyte Macrophage Colony-stimulating Factor
Cancer Res., November 15, 2004; 64(22): 8435 - 8442.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Rosato, S. D. Santa, A. Zoso, S. Giacomelli, G. Milan, B. Macino, V. Tosello, P. Dellabona, P.-L. Lollini, C. De Giovanni, et al.
The Cytotoxic T-Lymphocyte Response against a Poorly Immunogenic Mammary Adenocarcinoma Is Focused on a Single Immunodominant Class I Epitope Derived from the gp70 Env Product of an Endogenous Retrovirus
Cancer Res., May 1, 2003; 63(9): 2158 - 2163.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
D. J.J. Carr, P. Härle, and B. M. Gebhardt
The Immune Response to Ocular Herpes Simplex Virus Type 1 Infection
Experimental Biology and Medicine, May 1, 2001; 226(5): 353 - 366.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
G. Forni, P. L. Lollini, P. Musiani, and M. P. Colombo
Immunoprevention of Cancer: Is the Time Ripe?
Cancer Res., May 1, 2000; 60(10): 2571 - 2575.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.